Arvinas (ARVN) Net Cash Flow Growth (1y) (2018 - 2026)
Arvinas (ARVN) Net Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Arvinas | 529.92 Mn | -84.98 Mn | - | -185.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.13% |
| Dec 31, 2025 | 170.59% |
| Sep 30, 2025 | 82.16% |
| Jun 30, 2025 | -49.25% |
| Mar 31, 2025 | 91.28% |
| Dec 31, 2024 | -92.27% |
| Sep 30, 2024 | -425.11% |
| Jun 30, 2024 | 268.69% |
| Mar 31, 2024 | -557.46% |
| Dec 31, 2023 | 485.96% |
| Sep 30, 2023 | -42.82% |
| Jun 30, 2023 | -228.16% |
| Mar 31, 2023 | 206.30% |
| Dec 31, 2022 | 65.20% |
| Sep 30, 2022 | -80.48% |
| Jun 30, 2022 | 110.55% |
| Mar 31, 2022 | 81.02% |
| Dec 31, 2021 | -129.51% |
| Sep 30, 2021 | 207.14% |
| Jun 30, 2021 | -1,918.24% |